Additionally, innovative approaches combining miR-200c with other therapeutic agents, such as PD-L1 inhibitors and BRAF-targeted therapies, have demonstrated improved anti-tumor responses by enhancing immune cell infiltration into tumors [93]. Here, CD274 is linked to neoplasm.